Biopharma CDMO intelligence in a single search
Find the right CDMO for your program. We aggregate regulatory inspections, clinical trials, and financial data so you can evaluate manufacturing partners in 60 seconds instead of 6 weeks.
Built for biotech teams evaluating outsourced manufacturing partners.
Try:
AI-powered by Claude · Searches all data sources · Free to use
169
CDMOs tracked
30,541
Clinical studies
1,016
Regulatory records
Browse by modality
Example Result
What you'll see when you search
Every result shows what the data confirms, what's missing, and what to watch out for.
Results for:
94%
81.8
First CDMO site approved for commercial ADC manufacturing in the US, with 15+ years of conjugation experience. 22 matched clinical programs and 2 EMA GMP certificates demonstrate deep ADC track record.
✓ 2 FDA inspections with clean record
✓ 22 matched clinical programs
✓ 2 EMA GMP certificates
⚠ Both FDA inspections resulted in VAI — minor observations, no enforcement action
91%
78.6
End-to-end ADC solution from pre-clinical through commercial scale. Holds 3 EMA GMP certificates and 4 MHRA GMP certificates. 92 press articles indicate significant market activity and expanding capacity.
✓ 3 EMA GMP certificates
✓ 4 MHRA GMP certificates
✓ Expanding ADC capacity
⚠ 9 FDA 483 citations on record — review specifics for relevance to ADC operations
87%
67.0
Purpose-built ADC bioconjugation facility with 500L conjugation train and $100M+ invested in ADC modalities. Recently acquired GSK Maryland facility to expand US manufacturing footprint.
✓ 88 press articles — high market activity
✓ 0 warning letters
✓ Purpose-built ADC bioconjugation facility
⚠ No FDA inspection data for ADC-specific site — regulatory track record not yet established